Clinical Trial Results: Heart Failure

Product Name: Dilatrend [carvedilol]
Date of Report: 12/19/2003
Phase: III
A multicenter randomized double-blind, controlled study to compare the effect on mortality and morbidity over 46–74 months of carvedilol (Dilatrend) (oral titrated administration of 6.25 mg bid to 25 mg bid, with a preceding dose of 3.125 mg bid) and metoprolol (oral titrated administration of 12.5 mg bid to 50 mg bid with a preceding dose of 5 mg bid) in patients with chronic heart failure (NYHA II-IV).

Product Name: Dilatrend [carvedilol]
Date of Report: To be Published
Phase: IV
CALL study. A Study of the Influence of Dilatrend (Carvedilol) on Physical Fitness and Quality of Life in Patients With Heart Failure

Product Name: Dilatrend [carvedilol]
Date of Report: 3/23/2006
Phase: IV
Tolerability of Carvedilol Therapy in Elderly Patients with Congestive Heart Failure: The COLA II Study

Product Name: ELECSYS®proBNP
Date of Report: To be Published
'BATTLE-SCARRED Study : A Study of Brain Natriuretic Peptide (BNP)-Assisted Treatment in Patients With Congestive Heart Failure

Product Name: ELECSYS®proBNP
Date of Report: To be Published
‘PROBE Study' : A Study of NT-Pro-Brain Natriuretic Peptide (NT-proBNP) Levels in Patients Hospitalized With Heart Failure

Product Name: ELECSYS®proBNP
Date of Report: To be Published
A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients With Acute Heart Failure.

Product Name: Elecsys®proBNP, Cardiac reader®proBNP
Date of Report: To be Published
A Randomised Trial of NT-proBNP Guided Patient Management in Heart Failure Clinics—A Study in the Danish Network of Heart Failure Clinics